RESUMEN
BACKGROUND: Inappropriate antimicrobial prescribing may harm patients and drive antimicrobial resistance. Junior doctors' knowledge of infectious diseases and antimicrobial prescribing is inadequate. Online spaced case-based learning can improve knowledge. OBJECTIVE: To develop infectious diseases and antimicrobial prescribing course content for online spaced education and assess its effectiveness and feasibility for junior doctors. METHODS: Infectious diseases and antimicrobial course content was developed for an online spaced education platform (Qstream Inc., Burlington, MA). Junior doctors (postgraduate years 1-3) at two tertiary teaching hospitals in Sydney participated in the study. Course content was provided with Qstream at one hospital and at the other hospital via two face-to-face (FTF) tutorials from August to October 2017. Knowledge and self-confidence were compared before and after training within and between both cohorts. RESULTS: Participation in the course was higher in the Qstream cohort with 48/127 (37.8%) completing the course compared with 44/110 (40%) attending one or both FTF sessions, of whom 22/110 (20%) attended both. Improvement in mean knowledge score from 69.7% to 81.5% in the Qstream cohort was significantly greater than the FTF cohort's minimal improvement from 67.6% to 67.9% (95% CI 2.79-20.33; P=0.01). In the Qstream cohort mean confidence rating (0-10) improvement from 5.14 to 6.55 was greater than the FTF group improvement from 5.37 to 5.85 (95% CI 0.132-1.171; P=0.02). Qstream feedback was very positive. CONCLUSIONS: Online spaced education in infectious diseases and antimicrobial prescribing was feasible, acceptable and effective for junior doctors. It has potential to reduce inappropriate antimicrobial prescribing and warrants further investigation.
Asunto(s)
Antibacterianos , Enfermedades Transmisibles , Antibacterianos/uso terapéutico , Enfermedades Transmisibles/tratamiento farmacológico , Hospitales de Enseñanza , Humanos , Prescripción InadecuadaRESUMEN
Women comprise a minority population of individuals living with HIV in Australia, and are often poorly represented in research and clinical trials so their needs remain largely unknown. Data suggests that they are diagnosed later than men and start antiretroviral therapy at a lower CD4 cell count. This raises the question whether there are sex specific barriers to linkage and retention in care. This study analyzed 484 surveys received from clinicians collecting demographic, virological, and reproductive health data along with perceived barriers to linkage and retention in care. Most women (67%) were estimated to have been linked into care within 28 days of diagnosis. For women who were not linked into care for more than 28 days, the most commonly reason cited was fear of disclosure to others, followed by fear of disclosure to their partner. The main reasons given for non-retention in care were related to transport, carer responsibilities, financial pressure, health beliefs and concern about stigma or disclosure.
Asunto(s)
Continuidad de la Atención al Paciente/estadística & datos numéricos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/psicología , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Retención en el Cuidado , Estigma Social , Adulto , Citas y Horarios , Australia/epidemiología , Empleo , Femenino , Infecciones por VIH/epidemiología , Humanos , Renta , Masculino , Persona de Mediana Edad , Grupos Minoritarios , Parejas Sexuales , Factores Socioeconómicos , Encuestas y Cuestionarios , Revelación de la VerdadRESUMEN
BACKGROUND: Suboptimal antibiotic use in respiratory infections is widespread in hospital medicine and primary care. Antimicrobial stewardship (AMS) teams within hospitals, commonly led by infectious diseases physicians, are frequently charged with optimizing the use of respiratory antibiotics, but there is limited information on what drives antibiotic use in this area of clinical medicine, or on how AMS is perceived. AIM: To explore the perceptions of hospital respiratory clinicians on AMS in respiratory medicine. METHODS: In-depth interviews were conducted with 28 clinicians (13 doctors and 15 nurses) from two hospitals in Australia. Data were analysed thematically using the framework approach. FINDINGS: Four key barriers to the integration of AMS processes within respiratory medicine, from the participants' perspectives, were identified: CONCLUSIONS: AMS processes are introduced in hospitals with established social structures and knowledge bases. This study found that AMS in respiratory medicine challenges and conflicts with many of these dynamics. If the influence of these dynamics is not considered, AMS processes may not be effective in containing antibiotic use in hospital respiratory medicine.
Asunto(s)
Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos/métodos , Actitud del Personal de Salud , Aceptación de la Atención de Salud , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Australia , Hospitales , Humanos , Entrevistas como AsuntoRESUMEN
OBJECTIVES: This study aimed to examine how hospital doctors balance competing concerns around antibiotic use and resistance, with a focus on individual care versus broader public health considerations. METHODS: Sixty-four doctors across two hospitals in Australia participated in semi-structured interviews about their perspectives on antibiotic resistance and prescribing decisions. Results were analysed using the framework approach. RESULTS: The first theme focused on the significance of antimicrobial resistance (AMR) and the role of hospital doctors. Participants did not perceive resistance to be central to clinical decision-making, and externalised the resistance threat. They perceived themselves as separated from the issue of escalating resistance, viewing the key drivers to be overseas use, use in agriculture, and community prescribing. The second theme was around balancing risks. Immediate clinical risks were described as prioritised over long term population risk. Participants described concern around reputational and legal risks, which were perceived to be associated with under-prescribing of antibiotics. Over-prescribing was described by participants to be easier and without perceived immediate risk to them or to patients. CONCLUSION: Hospital doctors perceived antimicrobial resistance as externally produced and described clinical concerns taking precedence in individual antibiotic decisions. These dual processes mean that a population health model has limited traction in the hospital context. The externalisation of resistance leads to a sense of futility in changing practice, which combines with the pressures of acute medicine to prioritise immediate patient outcomes. Such dynamics are leading to antibiotic optimisation as a low or absent priority in hospital clinician antibiotic decision-making.
RESUMEN
BACKGROUND: Antibiotic optimization in hospitals is an increasingly critical priority in the context of proliferating resistance. Despite the emphasis on doctors, optimizing antibiotic use within hospitals requires an understanding of how different stakeholders, including non-prescribers, influence practice and practice change. AIM: This study was designed to understand Australian hospital managers' perspectives on antimicrobial resistance, managing antibiotic governance, and negotiating clinical vis-à-vis managerial priorities. METHODS: Twenty-three managers in three hospitals participated in qualitative semi-structured interviews in Australia in 2014 and 2015. Data were systematically coded and thematically analysed. FINDINGS: The findings demonstrate, from a managerial perspective: (1) competing demands that can hinder the prioritization of antibiotic governance; (2) ineffectiveness of audit and monitoring methods that limit rationalization for change; (3) limited clinical education and feedback to doctors; and (4) management-directed change processes are constrained by the perceived absence of a 'culture of accountability' for antimicrobial use amongst doctors. CONCLUSION: Hospital managers report considerable structural and interprofessional challenges to actualizing antibiotic optimization and governance. These challenges place optimization as a lower priority vis-à-vis other issues that management are confronted with in hospital settings, and emphasize the importance of antimicrobial stewardship (AMS) programmes that engage management in understanding and addressing the barriers to change.
Asunto(s)
Antibacterianos/uso terapéutico , Utilización de Medicamentos/normas , Hospitales , Administración de la Práctica Médica , Australia , Femenino , Humanos , Entrevistas como Asunto , Masculino , Política OrganizacionalRESUMEN
BACKGROUND: The role of infectious diseases (ID) and clinical microbiology (CM) in hospital settings has expanded in response to increasing antimicrobial resistance, leading to widespread development of hospital antimicrobial stewardship (AMS) programmes, the majority of which include antibiotic approval systems. However, inappropriate antibiotic use in hospitals continues, suggesting potential disjunctions between technical advice and the logics of antibiotic use within hospitals. AIM: To examine the experiences of doctors in a UK hospital with respect to AMS guidance of antibiotic prescribing, and experiences of a verbal postprescription antibiotic approval process. METHODS: Twenty doctors in a teaching hospital in the UK participated in semi-structured interviews about their experiences of antibiotic use and governance. NVivo10 software was used to conduct a thematic content analysis systematically. FINDINGS: This study identified three key themes regarding doctors' relationships with ID/CM clinicians that shaped their antibiotic practices: (1) competing hierarchical influences limiting active consultation with ID/CM; (2) non-ID/CM consultants' sense of ownership over clinical decision-making and concerns about challenges to clinical autonomy; and (3) tensions between evidence-based practice and experiential-style learning. CONCLUSIONS: This study illustrates the importance of examining relations between ID/CM and non-ID/CM clinicians in the hospital context, indicating that AMS models that focus exclusively on delivering advice rather than managing interprofessional relationships may be limited in their capacity to optimize antibiotic use. AMS and, specifically, antibiotic approval systems would likely be more effective if they incorporated time and resources for fostering and maintaining professional relationships.
Asunto(s)
Antiinfecciosos/uso terapéutico , Enfermedades Transmisibles/tratamiento farmacológico , Utilización de Medicamentos/normas , Adhesión a Directriz , Pautas de la Práctica en Medicina , Femenino , Hospitales de Enseñanza , Humanos , Relaciones Interprofesionales , Entrevistas como Asunto , Masculino , Investigación Cualitativa , Reino UnidoRESUMEN
The use of antiretroviral therapy to prevent HIV transmission is now advocated in many settings, yet little research has documented the views of people with HIV. Semi-structured interviews were conducted in Australia between 2012 and 2014 with 27 HIV-positive people not using treatment at the time of interview. Thematic analysis of views on treatment-as-prevention found that while many participants recognised potential prevention benefits, only a minority was in support of initiating treatment solely to achieve those benefits. A range of uncertain or critical views were expressed regarding who would benefit, risk reduction, and changing treatment norms. Participants resisted responsibility narratives that implied treatment should be used for the public good, in favour of making considered decisions about their preferred approach to managing HIV. Engaging communities in dialogue and debate regarding the risks and benefits of treatment will be critical if this new prevention strategy is to engender public trust.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/prevención & control , Conducta de Reducción del Riesgo , Adulto , Anciano , Australia , Femenino , Humanos , Entrevistas como Asunto , Masculino , Persona de Mediana Edad , Análisis Multivariante , Embarazo , Investigación Cualitativa , Análisis de RegresiónAsunto(s)
Diagnóstico Tardío , Infecciones por VIH/diagnóstico , Hepatitis B Crónica/diagnóstico , Hepatitis C Crónica/diagnóstico , Adulto , Anciano , Diagnóstico Tardío/efectos adversos , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/virología , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/virología , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Long-term outcomes of HIV-infected patients admitted to the intensive care unit (ICU) since the advent of combination antiretroviral therapy (cART) have not been well described. We reviewed the long-term outcomes and clinical follow-up of HIV-infected patients admitted to the Prince of Wales Hospital ICU between 1999 and 2005 by a retrospective medical record review. Mortality was assessed in the ICU, in hospital and in the long-term. Twenty-four HIV-infected male patients underwent 26 ICU admissions. Their ICU and in-hospital mortalities were 33% and 46%, respectively. Higher APACHE (acute physiology and chronic health evaluation) II scores (median 27 versus 12, P < 0.001), lower CD4 cell counts (median 45 versus 335 cells/µL, P = 0.041) and longer hospitalization times prior to ICU admission (median 4 versus 1 day, P = 0.02) were significantly associated with in-hospital mortality. We found 85% of the subjects who survived hospital admission were still alive at a median of 41 months (4 months to 5 years) of follow-up, all of who were functionally independent. HIV-infected patients who survived ICU admission at our institution had good long-term outcomes in the cART era.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/mortalidad , APACHE , Adulto , Anciano , Antirretrovirales/uso terapéutico , Australia/epidemiología , Infecciones por VIH/epidemiología , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Admisión del Paciente/estadística & datos numéricos , Estudios Retrospectivos , Resultado del TratamientoAsunto(s)
Fármacos Anti-VIH/uso terapéutico , Linfoma Relacionado con SIDA/tratamiento farmacológico , Linfoma de Células B de la Zona Marginal/tratamiento farmacológico , Neoplasias Nasofaríngeas/tratamiento farmacológico , Recuento de Linfocito CD4 , Humanos , Lamivudine/uso terapéutico , Lopinavir , Linfoma Relacionado con SIDA/radioterapia , Linfoma de Células B de la Zona Marginal/etiología , Masculino , Persona de Mediana Edad , Neoplasias Nasofaríngeas/etiología , Neoplasias Nasofaríngeas/radioterapia , Pirimidinonas/uso terapéutico , Radioterapia Adyuvante , Inducción de Remisión , Ritonavir/uso terapéutico , Carga Viral , Zidovudina/uso terapéuticoRESUMEN
Not all people with tuberculosis have their HIV status ascertained despite the interaction between these infections. We investigated the self-reported HIV testing practice among physicians treating tuberculosis in Australia and New Zealand and used logistic regression to assess factors associated with a routine offer of HIV testing in cases of tuberculosis. Of 290 subjects, 61% always recommended an HIV test for a 38-year-old married man with smear-positive pulmonary tuberculosis. A lower proportion (40%) always tested a 78-year-old man or a female patient (58%), and more always HIV tested a South African case (85%), a patient with oral candidiasis (87%) or an unmarried male patient (66%). No scenario was associated with a universal offer of HIV testing. Clinician factors such as specialty (odds ratio [OR] 3.09), jurisdiction of practice (OR 4.09) and number of HIV tests requested in the past five years (OR 0.29) predicted the self-reported frequency of always HIV testing tuberculosis patients. At least 48% of respondents reported that epidemiological or clinical factors influenced their decision to offer testing. Strategies to increase HIV testing in cases of tuberculosis need to consider clinician factors.
Asunto(s)
Toma de Decisiones , Infecciones por VIH/diagnóstico , Tamizaje Masivo/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Tuberculosis/epidemiología , Adulto , Australia , Femenino , Humanos , Modelos Logísticos , Masculino , Medicina , Persona de Mediana Edad , Nueva Zelanda , Ubicación de la Práctica ProfesionalAsunto(s)
Diagnóstico Tardío , Infecciones por VIH/diagnóstico , VIH , Tuberculosis Pulmonar/terapia , Adulto , Anciano de 80 o más Años , Diagnóstico Tardío/prevención & control , VIH/aislamiento & purificación , Infecciones por VIH/complicaciones , Humanos , Masculino , Factores de Riesgo , Resultado del Tratamiento , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/etiologíaRESUMEN
Enfuvirtide is beneficial in patients with limited treatment options. We report this case to highlight the possibility of a delayed hypersensitivity reaction as an important potential side-effect of enfuvirtide treatment. A highly antiretroviral treatment-experienced man was commenced on a new regimen containing enfuvirtide. Prophylaxis for Pneumocystis jirovecii pneumonia was started using trimethoprim/sulphamethoxazole (TMP-STX) simultaneously. Ten days later, he developed a maculopapular rash on the chest and abdomen without any systemic features. Both enfuvirtide and TMP-STX were discontinued. Re-introduction of enfuvirtide occurred in a hospital setting. Before re-challenge, haemodynamic observations were stable. The rash re-appeared involving the whole body 5 hours post-dose and was associated with fever (temperature 38.4), nausea and a presyncopal episode. Hypersensitivity to this drug occurred immediately post-dose in phase III trials. Enfuvirtide is a useful drug in those with reduced drug options. The possibility of delayed hypersensitivity has not been reported previously.
Asunto(s)
Hipersensibilidad a las Drogas/inmunología , Exantema/inmunología , Proteína gp41 de Envoltorio del VIH/efectos adversos , Inhibidores de Fusión de VIH/efectos adversos , VIH-1 , Hipersensibilidad Tardía/inmunología , Fragmentos de Péptidos/efectos adversos , Terapia Antirretroviral Altamente Activa , Enfuvirtida , Proteína gp41 de Envoltorio del VIH/uso terapéutico , Inhibidores de Fusión de VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/uso terapéuticoRESUMEN
The mortality of retained, infected pacemaker systems is high. We assessed the safety and rate of relapse of infection after complete percutaneous removal of leads of infected pacemaker systems. None of the 40 subjects experienced procedure-related mortality and there were no cases of relapse after a median duration of follow up of 8 years (range, 3 months to 12 years). Procedure-related complications and other adverse events during therapy are reported. Percutaneous removal of infected pacemakers in conjunction with appropriate antibiotic therapy is safe and effective.
Asunto(s)
Remoción de Dispositivos , Marcapaso Artificial/microbiología , Infecciones Relacionadas con Prótesis/terapia , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Arritmias Cardíacas/terapia , Bacteriemia/etiología , Bacteriemia/terapia , Desfibriladores Implantables/efectos adversos , Desfibriladores Implantables/microbiología , Endocarditis/etiología , Endocarditis/terapia , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Osteomielitis/etiología , Osteomielitis/terapia , Marcapaso Artificial/efectos adversos , Infecciones Relacionadas con Prótesis/etiología , Recurrencia , Estudios Retrospectivos , Infección de la Herida Quirúrgica/etiología , Infección de la Herida Quirúrgica/terapia , Resultado del TratamientoRESUMEN
OBJECTIVE: The aim of the study was to investigate symptoms of long-term central nervous system (CNS) toxicity in HIV-positive patients treated with efavirenz (EFV). METHODS: We carried out a single-centre, cross-sectional case-control study comparing patients treated with EFV for at least 6 months with a matched control group. Self-administered, standardized questionnaires including the Depression, Anxiety and Stress Scales (DASS), the Cognitive Failures Questionnaire (CFQ) and a questionnaire on unusual dreams, insomnia, fatigue, dizziness, depersonalization and derealization were administered. RESULTS: Data for 32 matched pairs were analysed. Significantly higher total stress scores (P=0.008) were found in the EFV group. Of the patients in this group, 19% also reported severe to extremely severe levels of stress (P=0.014), indicating increased difficulty in relaxing, and being more irritable, impatient, agitated and easily upset. Nineteen per cent of patients treated with EFV also reported severe levels of anxiety (P=0.059) as assessed with the DASS scale. This patient group also reported a higher rate of unusual dreams (P=0.049). No significant differences between groups were found for measures of cognitive impairments, fatigue, dizziness, derealization or depersonalization. CONCLUSION: EFV-treated patients reported higher levels of severe stress and anxiety as well as a higher rate of unusual dreams than patients not treated with EFV. These differences may be an expression of persisting CNS side effects in patients who remain on EFV for a prolonged period.
Asunto(s)
Síntomas Conductuales/epidemiología , Infecciones por VIH/epidemiología , Trastornos Mentales/epidemiología , Adulto , Alquinos , Australia/epidemiología , Síntomas Conductuales/inducido químicamente , Benzoxazinas/efectos adversos , Estudios de Casos y Controles , Estudios Transversales , Ciclopropanos , Sueños , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Trastornos Mentales/inducido químicamente , Pruebas Neuropsicológicas , Prevalencia , Inhibidores de la Transcriptasa Inversa/efectos adversos , Autorrevelación , Estrés Psicológico/inducido químicamente , Estrés Psicológico/epidemiologíaRESUMEN
Peripheral nervous system complications of Q fever are uncommon. A case of electrophysiologically documented brachial neuritis occurring during acute Coxiella burnetii infection is reported. The relevant literature is reviewed.
Asunto(s)
Neuritis del Plexo Braquial/etiología , Fiebre Q/complicaciones , Enfermedad Aguda , Adulto , Humanos , Masculino , Fiebre Q/fisiopatologíaRESUMEN
Traditional HIV epidemic models suggest that rapid disease progression may lead to reduced transmission because of a decreased time for the spread of the virus. We present a transmission model structured by age and duration of infection, and propose that rapid disease progression may lead to higher viraemia at a younger age, when individuals are more sexually active. We suggest that rapid disease progression should be considered as a factor in the scale of the HIV epidemic in Africa.
Asunto(s)
Brotes de Enfermedades , Infecciones por VIH/epidemiología , Infecciones por VIH/fisiopatología , Adulto , Progresión de la Enfermedad , Humanos , Incidencia , Conducta SexualRESUMEN
Clinically apparent hepatitis C virus (HCV) infection developed in a prison inmate after two tattooing episodes within the recognised incubation period for HCV infection. Seroconversion and HCV viraemia with subsequent resolution of hepatitis and loss of plasma viraemia were documented. Introducing licensed tattooists, and thereby improving infection control practices, may reduce the risk of hepatitis C virus infection in prisons.